Latest Breaking News On - Aim leukemia - Page 3 : comparemela.com

Curis Provides Second Quarter 2023 Business Update

Removal of partial clinical hold – enrolling patients at confirmed RP2D in the TakeAim Leukemia Study Enrolling patients in the TakeAim Lymphoma Study in combination with ibrutinib Strong balance.

United statesJames dentzerExchange commissionRoche groupDrug administrationPrnewswire curis incCuris incTakeaim leukemiaTakeaim lymphoma studyRecent operationalTakeaim leukemia phaseAcute myelogenous leukemiaMyelodysplastic syndromesTakeaim lymphomaJuly registered directAim lymphoma

Curis to Release Second Quarter 2023 Financial Results and Hold Conference Call on August 3, 2023

Curis to Release Second Quarter 2023 Financial Results and Hold Conference Call on August 3, 2023
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesPrnewswire curis incRoche groupCuris incDrug administrationAim lymphomaAim leukemiaOrphan drug designation

Curis to Release Second Quarter 2023 Financial Results and Hold Conference Call on August 3, 2023

United statesCuris incDrug administrationPrnewswire curis incRoche groupAim lymphomaAim leukemiaOrphan drug designation

Curis to Release Second Quarter 2023 Financial Results and Hold Conference Call on August 3, 2023

LEXINGTON, Mass., July 27, 2023 /PRNewswire/ Curis, Inc. , a biotechnology company focused on the development of emavusertib, an orally available, small molecule IRAK4 inhibitor for the treatment.

United statesPrnewswire curis incCuris incDrug administrationRoche groupAim lymphomaAim leukemiaOrphan drug designation

Curis, Inc - FDA Removes Partial Clinical Hold on TakeAim Leukemia Study RP2D Established at 300 mg BID

LEXINGTON - Curis, Inc., , a biotechnology company focused on the development of emavusertib, an orally available small molecule triple target inhibitor for the treatment of hematologic.

Stephanie ascherJames dentzerCuris incClinical development of curisRoche groupDrug administrationExchange commissionTakeaim leukemia phaseAcute myelogenous leukemiaMyelodysplastic syndromesTakeaim leukemiaChief executive officerComplete responsePartial hematologic recoverySenior vice presidentClinical development